5alpha-Reductase inhibitor treatment of prostatic diseases: background and practical implications.
作者： J Dörsam , J Altwein
DOI: 10.1038/PCAN.2008.56
关键词: Prostate cancer 、 Prostatic Diseases 、 Medicine 、 5alpha-reductase 、 Practical implications 、 Bioinformatics 、 Pharmacology
摘要: 5α-Reductase inhibitor treatment of prostatic diseases: background and practical implications
nature.com
sci-hub.se 参考文章(63)
W.A. Sakr, G.P. Haas, B.F. Cassin, J.E. Pontes, J.D. Crissman, The Frequency of Carcinoma and Intraepithelial Neoplasia of the Prostate in Young Male Patients The Journal of Urology. ,vol. 150, pp. 379- 385 ,(1993) , 10.1016/S0022-5347(17)35487-3
M. Marberger, J. Adolfsson, A. Borkowski, J. Fitzpatrick, D. Kirk, D. Prezioso, C. Rabaça, E. Solsona, P. Teillac, The clinical implications of the prostate cancer prevention trial. BJUI. ,vol. 92, pp. 667- 671 ,(2003) , 10.1046/J.1464-410X.2003.04486.X
Yuan-Shan Zhu, Li-Qun Cai, Xueke You, Juan J. Cordero, Ying Huang, Julianne Imperato-McGinley, Androgen-Induced Prostate-Specific Antigen Gene Expression Is Mediated via Dihydrotestosterone in LNCaP Cells Journal of Andrology. ,vol. 24, pp. 681- 687 ,(2003) , 10.1002/J.1939-4640.2003.TB02727.X
A. Jemal, R. Siegel, E. Ward, T. Murray, J. Xu, C. Smigal, M. J. Thun, Cancer statistics, 2006. CA: A Cancer Journal for Clinicians. ,vol. 56, pp. 106- 130 ,(2006) , 10.3322/CANJCLIN.56.2.106
Ferran Algaba, Jonathan I. Epstein, Hector C. Aldape, George M. Farrow, Antonio Lopez-Beltran, John Maksem, Roberto E. Orozco, Anna Pacelli, Thomas M. Pisansky, Isabel Trias, Workgroup 5: Assessment of prostate carcinoma in core needle biopsy--Definition of minimal criteria for the diagnosis of cancer in biopsy material Cancer. ,vol. 78, pp. 376- 381 ,(1996) , 10.1002/(SICI)1097-0142(19960715)78:2<376::AID-CNCR32>3.0.CO;2-R
M Speakman, J Batista, R Berges, E Chartier-Kastler, G Conti, F Desgrandchamps, K Dreikorn, F Lowe, M O'Leary, M Perez, J Trachtenberg, A Tubaro, B Meesen, L Smets, H Stoevelaar, Integrating risk profiles for disease progression in the treatment choice for patients with lower urinary tract symptoms/benign prostatic hyperplasia: a combined analysis of external evidence and clinical expertise. Prostate Cancer and Prostatic Diseases. ,vol. 8, pp. 369- 374 ,(2005) , 10.1038/SJ.PCAN.4500827
GEORG SCHATZL, STEPHAN MADERSBACHER, ANDREA HAITEL, ANDREA GSUR, MARTIN PREYER, GERALD HAIDINGER, CHRISTA GASSNER, MICHAELA OCHSNER, MICHAEL MARBERGER, Associations of serum testosterone with microvessel density, androgen receptor density and androgen receptor gene polymorphism in prostate cancer. The Journal of Urology. ,vol. 169, pp. 1312- 1315 ,(2003) , 10.1097/01.JU.0000056900.26628.16
Kevin M. Slawin, Michael W. Kattan, Claus G. Roehrborn, Timothy Wilson, Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia Urology. ,vol. 67, pp. 84- 88 ,(2007) , 10.1016/J.UROLOGY.2005.07.013
Al Baha Barqawi, Judd W Moul, Ali Ziada, Liann Handel, E.David Crawford, Combination of low-dose flutamide and finasteride for PSA-only recurrent prostate cancer after primary therapy ☆ Urology. ,vol. 62, pp. 872- 876 ,(2003) , 10.1016/S0090-4295(03)00667-8
J Barkin, M Guimaraes, G Jacobi, D Pushkar, S Taylor, OB van Vierssen Trip, Alpha-Blocker Therapy Can Be Withdrawn in the Majority of Men Following Initial Combination Therapy with the Dual 5α-Reductase Inhibitor Dutasteride European Urology. ,vol. 44, pp. 461- 466 ,(2003) , 10.1016/S0302-2838(03)00367-1